TNFRSF9 and neoplasm: Consistent with our previous findings using agonistic CD137 antibodies, treatment with rhCD137L-MSNs promoted the production of tumor-associated cytokines, specifically IL-6 and IL-8 by C666-CD137 cells, and IL-8 by HK1-CD137 cells (Figure S6A-B) 19.